Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit
”From a commercial perspective, this is a huge opportunity for us,” says Bavarian Nordic’s former chairman, Gerard van Odijk.
by marketwire, translated by daniel pedersen
Bavarian Nordic’s position in the competition to bring out a vaccine against respiratory syncytial virus (RSV) has improved now that Johnson & Johnson has bowed out. On Wednesday, the pharmaceutical giant dropped its candidate after assessing the competitive landscape.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
